close

For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked #1 in the Americas for number of technology deals in 2015 by Mergermarket
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney

MORE >

We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500

San Francisco Office
555 California Street
13th Floor
San Francisco, CA 94104
415.875.2300

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510

New York Office
1211 Avenue of the Americas
32nd Floor
New York, NY 10036
212.921.2001

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200

相关内容

​​ ​​​​

近期科技与生命科学行业首次公开募股的关键指标报告-2014 年上半年

September 16, 2014

​本报告分析了于 2014 年上半年上市的 76 家科技及生命科学公司首次公开募股(IPO)的主要方面。这份对本公司年度IPO调查的半年更新是为我们的客户、朋友及其他有意进一步挖掘近期IPO动向、探索数据中体现趋势的读者而编撰的。下载完整报告,您将可查看各种对关键参数提供直观概览、展现近期趋势动向的图表。

关键结论:

  • 2014 年上半年延续了 2013 年的快速步伐。生命科学公司表现尤其活跃,共完成 43 宗交易,高于科技行业的 33 宗。
  • 在完成 IPO 的科技公司中,接近 60% 的公司募集资金超过 1 亿美元,而略多于 20% 的公司募集资金超过 2 亿美元。在完成 IPO 的生命科学公司中,募集资金超过 1 亿美元的公司不足 20%,募集资金超过 2 亿美元的公司低于 5%。
  • 在完成 IPO 的生命科学公司中,44% 的股价低于其红头招股书中列出的范围, 而科技行业中仅有 15% 的公司的股价低于其红头招股书范围。
  • 2014 年上半年,IPO 发行人的后续发行也持续为投资人青睐。在 2013 年下半年完成 IPO 的 45 家科技或生命科学公司中,有 13 家在首次公开募股后 180 天内完成了后续发行。
  • 在 2014 年完成 IPO 的科技和生命科学公司中,14 家公司的总部在美国之外,其中六家在中国,五家在欧洲,两家在以色列,一家在加拿大。
​​​​​​​